Vascular endothelial growth factor-A: A multifunctional molecular player in diabetic retinopathy

International Journal of Biochemistry and Cell Biology

Volumn 41, Issue 12, 2009, Pages 2368-2371

  Zhang, Xinyuan ^a,b   Bao, Shisan ^c   Hambly, Brett D ^c   Gillies, Mark C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Institute for Biomedical Research   (Australia)

Author keywords

Angiogenesis; Anti VEGF therapy; Diabetic retinopathy; Vascular endothelial growth factor A

Indexed keywords

BEVACIZUMAB; GLUCOCORTICOID; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

AMINO ACID SEQUENCE; BLOOD VESSEL PERMEABILITY; CATARACT; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; HUMAN; INTRAOCULAR PRESSURE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETINA NERVE CELL; SHORT SURVEY; SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CAPILLARY PERMEABILITY; CYTOPROTECTION; DIABETIC RETINOPATHY; HUMANS; IMMUNOTHERAPY; NEOVASCULARIZATION, PATHOLOGIC; RETINAL NEURONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350539302     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2009.07.011     Document Type: Short Survey

References (20)

1. Barber A.J., and Antonetti D.A. Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats. Invest Ophthalmol Vis Sci 44 (2003) 5410-5416
2. Barber A.J., Lieth E., Khin S.A., Antonetti D.A., Buchanan A.G., and Gardner T.W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102 (1998) 783-791
3. Bhisitkul R.B., Winn B.J., Lee O.T., Wong J., Pereira Dde S., Porco T.C., et al. Neuroprotective effect of intravitreal triamcinolone acetonide against photoreceptor apoptosis in a rabbit model of subretinal hemorrhage. Invest Ophthalmol Vis Sci 49 (2008) 4071-4077
4. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
5. Byrne A.M., Bouchier-Hayes D.J., and Harmey J.H. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9 (2005) 777-794
6. Cunningham Jr. E.T., Adamis A.P., Altaweel M., Aiello L.P., Bressler N.M., D'Amico D.J., et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 (2005) 1747-1757
7. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
8. Gillies M.C., Sutter F.K., Simpson J.M., Larsson J., Ali H., and Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113 (2006) 1533-1538
9. Hall E.D. Neuroprotective actions of glucocorticoid and nonglucocorticoid steroids in acute neuronal injury. Cell Mol Neurobiol 13 (1993) 415-432
10. Hammes H.P., Lin J., Bretzel R.G., Brownlee M., and Breier G. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 47 (1998) 401-406
11. Harhaj N.S., Felinski E.A., Wolpert E.B., Sundstrom J.M., Gardner T.W., and Antonetti D.A. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci 47 (2006) 5106-5115
12. Kamba T., Tam B.Y., Hashizume H., Haskell A., Sennino B., Mancuso M.R., et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290 (2006) H560-H576
13. Kroll P., Rodrigues E.B., and Hoerle S. Pathogenesis and classification of proliferative diabetic vitreoretinopathy. Ophthalmologica 221 (2007) 78-94
14. Nishijima K., Ng Y.S., Zhong L., Bradley J., Schubert W., Jo N., et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171 (2007) 53-67
15. Oshitari T., Yamamoto S., Hata N., and Roy S. Mitochondria- and caspase-dependent cell death pathway involved in neuronal degeneration in diabetic retinopathy. Br J Ophthalmol 92 (2008) 552-556
16. Perrin R.M., Konopatskaya O., Qiu Y., Harper S., Bates D.O., and Churchill A.J. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 48 (2005) 2422-2427
17. Price S.A., Dent C., Duran-Jimenez B., Liang Y., Zhang L., Rebar E.J., et al. Gene transfer of an engineered transcription factor promoting expression of VEGF-A protects against experimental diabetic neuropathy. Diabetes 55 (2006) 1847-1854
18. Wenzel A., Grimm C., Seeliger M.W., Jaissle G., Hafezi F., Kretschmer R., et al. Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor. Invest Ophthalmol Vis Sci 42 (2001) 1653-1659
19. Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 14 (2005) 207-221
20. Zhang X., Bao S., Lai D., Rapkins R.W., and Gillies M.C. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 57 (2008) 1026-1033